216 related articles for article (PubMed ID: 7529011)
1. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.
Boyer PL; Ding J; Arnold E; Hughes SH
Antimicrob Agents Chemother; 1994 Sep; 38(9):1909-14. PubMed ID: 7529011
[TBL] [Abstract][Full Text] [Related]
2. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.
Jonckheere H; Taymans JM; Balzarini J; Velázquez S; Camarasa MJ; Desmyter J; De Clercq E; Anné J
J Biol Chem; 1994 Oct; 269(41):25255-8. PubMed ID: 7523383
[TBL] [Abstract][Full Text] [Related]
3. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
5. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; Tarpley WG; De Clercq E
J Virol; 1993 Sep; 67(9):5353-9. PubMed ID: 7688822
[TBL] [Abstract][Full Text] [Related]
6. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
Arion D; Fletcher RS; Borkow G; Camarasa MJ; Balzarini J; Dmitrienko GI; Parniak MA
Mol Pharmacol; 1996 Nov; 50(5):1057-64. PubMed ID: 8913335
[TBL] [Abstract][Full Text] [Related]
7. Chimeric HIV-1 and feline immunodeficiency virus reverse transcriptases: critical role of the p51 subunit in the structural integrity of heterodimeric lentiviral DNA polymerases.
Amacker M; Hübscher U
J Mol Biol; 1998 May; 278(4):757-65. PubMed ID: 9614940
[TBL] [Abstract][Full Text] [Related]
8. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors.
Balzarini J; Auwerx J; Rodríguez-Barrios F; Chedad A; Farkas V; Ceccherini-Silberstein F; García-Aparicio C; Velázquez S; De Clercq E; Perno CF; Camarasa MJ; Gago F
Mol Pharmacol; 2005 Jul; 68(1):49-60. PubMed ID: 15833734
[TBL] [Abstract][Full Text] [Related]
9. A two plasmid co-expression system in Escherichia coli for the production of virion-like reverse transcriptase of the human immunodeficiency virus type 1.
Jonckheere H; De Vreese K; Debyser Z; Vandekerckhove J; Balzarini J; Desmyter J; De Clercq E; Anné J
J Virol Methods; 1996 Sep; 61(1-2):113-25. PubMed ID: 8882944
[TBL] [Abstract][Full Text] [Related]
10. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.
Balzarini J; Karlsson A; Vandamme AM; Pérez-Pérez MJ; Zhang H; Vrang L; Oberg B; Bäckbro K; Unge T; San-Félix A
Proc Natl Acad Sci U S A; 1993 Aug; 90(15):6952-6. PubMed ID: 7688467
[TBL] [Abstract][Full Text] [Related]
12. Biochemical mechanism of HIV-1 resistance to rilpivirine.
Singh K; Marchand B; Rai DK; Sharma B; Michailidis E; Ryan EM; Matzek KB; Leslie MD; Hagedorn AN; Li Z; Norden PR; Hachiya A; Parniak MA; Xu HT; Wainberg MA; Sarafianos SG
J Biol Chem; 2012 Nov; 287(45):38110-23. PubMed ID: 22955279
[TBL] [Abstract][Full Text] [Related]
13. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
Rodríguez-Barrios F; Pérez C; Lobatón E; Velázquez S; Chamorro C; San-Félix A; Pérez-Pérez MJ; Camarasa MJ; Pelemans H; Balzarini J; Gago F
J Med Chem; 2001 Jun; 44(12):1853-65. PubMed ID: 11384232
[TBL] [Abstract][Full Text] [Related]
14. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1--interactions with primer tRNA(Lys3), initiation of cDNA synthesis, and effect of inhibitors.
Dufour E; El Dirani-Diab R; Boulmé F; Fournier M; Nevinsky G; Tarrago-Litvak L; Litvak S; Andreola ML
Eur J Biochem; 1998 Jan; 251(1-2):487-95. PubMed ID: 9492322
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer.
Wang J; Smerdon SJ; Jäger J; Kohlstaedt LA; Rice PA; Friedman JM; Steitz TA
Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7242-6. PubMed ID: 7518928
[TBL] [Abstract][Full Text] [Related]
16. Intramolecular chimeras of the p51 subunit between HIV-1 and FIV reverse transcriptases suggest a stabilizing function for the p66 subunit in the heterodimeric enzyme.
Tasara T; Amacker M; Hübscher U
Biochemistry; 1999 Feb; 38(5):1633-42. PubMed ID: 9931031
[TBL] [Abstract][Full Text] [Related]
17. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
[TBL] [Abstract][Full Text] [Related]
18. Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds.
Debyser Z; Pauwels R; Andries K; Desmyter J; Engelborghs Y; Janssen PA; De Clercq E
Mol Pharmacol; 1992 Jan; 41(1):203-8. PubMed ID: 1370707
[TBL] [Abstract][Full Text] [Related]
19. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
[TBL] [Abstract][Full Text] [Related]
20. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.
Braz VA; Holladay LA; Barkley MD
Biochemistry; 2010 Jan; 49(3):601-10. PubMed ID: 20039714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
